AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01230684 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM)
Description: The contrast agent will be prepared using a single, 3 mL vial of Optison and 57 mL saline combined in a sterile syringe. Contrast will be set to deliver a continuous infusion at 4 mL/min, via peripheral access. In the event that the above description of the administration of Optison is not adequate for lumen flow contrast enhancement the PI or Co-I will direct the study team to proceed to the secondary administration procedure. This will be done by the following: 0.5 mL of Optison will be injected into a peripheral vein. This may be repeated for further contrast enhancement as needed. The maximum total doses should not exceed 5.0 mL in any 10 minute period nor exceed 8.7 mL in any one patient study. We will follow the insert package dose. We will not not exceed 5.0 or 10 minutes or 8.7ml per patient (this will include the 0.5mL for initial). Therefore, no more that 8.2mL will given in this second administration procedure.
Study NCT03399682 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cystography
Description: observationnal study
Study NCT04463732 — intervention group
Intervention type: OTHER
Intervention: Loaded inspiratory muscle test and cardiopulmonary exercise test
Description: This is an observational study. Loaded inspiratory muscle test is setting at 30% of maximal inspiratory pressure. Subjects will perform only 15 breaths under this intensity to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training. Cardiopulmonary exercise test is performed by using bicycle ergometer. These two tests will be performed at least 1 week separately.
Study NCT00556205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Sunitinib orally once daily
Study NCT00556205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravenously every 14 days
Study NCT03903003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high flow nasal oxygen device (POİNT)
Description: With POINT device (peri-operative insufflatory nasal therapy); patients are heated at higher flow and applied to humidified oxygen.
Study NCT03903003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face mask
Description: In order to protect the mother from hypoxia, preoxygenation is performed with face mask before induction of anesthesia.
Study NCT01729533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: ICSI Sperm selection in the ICSI group is analyzed under a magnification of 400x using an inverted microscope. ICSI is performed in a micro-injection dish prepared with 4 µL droplets of buffered medium and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
Study NCT01729533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMSI
Description: Sperm selection in the IMSI group is analyzed at high magnification using an inverted microscope equipped with high-power differential interference contrast optics. The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei (\[1\] smooth, \[2\] symmetric, and \[3\] oval configuration) and \[4\] normal nuclear chromatin content (if it contained no more than one vacuole, which occupies \<4% of the nuclear area) are selected for injection.
Study NCT03808025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: opioid education
Description: see arm/group descriptions
Study NCT02934087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular Aneurysm Repair
Description: Endovascular aneurysm repair (or endovascular aortic repair) (EVAR) is a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA)
Study NCT01606748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: PK Run-In Period: Necitumumab administered on Day 3 of the 3-week PK run-in period as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Treatment Cycles: Necitumumab administered on Days 1 and 8 of every 3-week cycle as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Participants in Cohort 1 will receive necitumumab Process C drug product and participants in Cohort 2 will receive necitumumab Process D drug product
Study NCT01606748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: PK Run-In Period: Gemcitabine administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 1250 milligram per square meter (mg/m2)~Treatment Cycles: Gemcitabine administered on Days 1 and 8 of every 3-week cycle as an I.V. infusion at a dose of 1250 mg/m2
Study NCT01606748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: PK Run-In Period: Cisplatin administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 75 mg/m2~Treatment Cycles: Cisplatin administered on Day 1 of every 3-week cycle as an I.V. infusion at a dose of 75 mg/m2
Study NCT03216148 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FET-PET
Description: All participating patients will receive a FET PET-scan parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
Study NCT02028403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936559
Description: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg of BMS-936559, depending on which cohort participants are enrolled in, administered as an intravenous (IV) infusion
Study NCT02028403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BMS-936559
Description: Sodium chloride for injection 0.9%, USP, administered as an IV infusion
Study NCT02105389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Yoga Intervention
Study NCT02334176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided axillary plexus block with 1 injection
Description: The needle will be advanced until the tip is positioned just dorsal to the artery and 35ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
Study NCT02334176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided axillary plexus block with 2 injections
Description: The needle will be initially advanced toward musculocutaneous nerve and 7 ml of LA (lidocaine 1.5% with epinephrine 5µg/ml) is deposited around the nerve. The needle will be then advanced until the tip is positioned just dorsal to the artery and 28 ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
Study NCT02334176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 1.5% with epinephrine 5µg/ml
Description: 35 ml of lidocaine 1.5% with epinephrine 5µg/ml will be used to perform the axillary plexus block
Study NCT01904318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-73152 mesylate 40 mg
Description: IDP-73152 mesylate 40 mg single dose administration
Study NCT01904318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-73152 mesylate 80 mg
Description: IDP-73152 mesylate 80 mg single dose administration
Study NCT01904318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-73152 mesylate 160 mg
Description: IDP-73152 mesylate 160 mg single dose administration
Study NCT01904318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-73152 mesylate 320 mg
Description: IDP-73152 mesylate 320 mg single dose administration
Study NCT01904318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-73152 mesylate 640 mg
Description: IDP-73152 mesylate 640 mg single dose administration
Study NCT01904318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-73152 mesylate 1280 mg
Description: IDP-73152 mesylate 1280 mg single dose administration
Study NCT01904318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single dose administration
Study NCT04794413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin is a serotonin receptor inverse agonist used in treatment of psychosis in Parkinson's disease.
Study NCT00630747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Idursulfase
Description: Solution for intravenous infusion, 0.5 mg/kg once-weekly
Study NCT03499405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Navigator Intervention
Description: Caregivers will be paired with a culturally matched family navigator.
Study NCT04620954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: 2mg of Oregovomab is administered through IV on Weeks 1, 5, 9, 17.
Study NCT04620954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480mg of Nivolumab is administered through IV every 4 weeks (Weeks 9, 13, 17, 21).
Study NCT04620954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pegylated liposomal doxorubicin (PLD) and carboplatin are administered every 4 weeks through IV. The starting dose of PLD and carboplatin are 30mg/m\^2 and 5 AUC (Area Under the Curve) respectively.
Study NCT01590732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01590732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01590732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT01590732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Given IV
Study NCT04276610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Vision Reading Rehabilitation
Description: Following Time 1, participants will receive the full complement of vision rehabilitation services available and deemed suitable by their clinical staff and rehabilitation professionals of either rehabilitation centre, according to the provision of assistive devices and services regulated by the Quebec Health Insurance (RAMQ). These services are include but are not limited to: a full optometric exam to determine functional vision, including refraction and the prescription of appropriate near and distance glasses and optical devices, an assessment by a low vision therapist and/or occupational therapist, the loan provision of hand-held optical magnification devices, electronic non-optical magnification devices (e.g., portable or table-top closed-circuit televisions), or computer software for screen content magnification (e.g., ZoomText), with appropriate training and follow-up sessions in the home, if required.
Study NCT03690973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar socket preservation with graft and flap surgery
Description: Alveolar socket preservation with xenogenic bone graft and flap surgery
Study NCT03690973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement with bone using flapless surgery
Description: Immediate implant placement with xenogenic bone graft using flapless surgery
Study NCT03690973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement with bone using flap surgery
Description: Immediate implant placement with xenogenic bone graft using flap surgery
Study NCT03690973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alveolar socket preservation with graft and flapless surgery
Description: Alveolar socket preservation with xenogenic bone graft and flapless surgery
Study NCT03055468 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer support
Description: Peer support and antidepressant medications
Study NCT03055468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Description: Peer support and antidepressant medications
Study NCT03641534 — intervention group
Intervention type: PROCEDURE
Intervention: Lung Ultrasound examination
Description: Use of lung ultrasound to detect pulmonary complications
Study NCT03641534 — intervention group
Intervention type: PROCEDURE
Intervention: Compression ultrasonography (CUS)
Description: CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
Study NCT03641534 — intervention group
Intervention type: PROCEDURE
Intervention: Echocardiography
Description: Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
Study NCT03641534 — intervention group
Intervention type: PROCEDURE
Intervention: Inferior Vena Cava ultrasound
Description: Measurement of the inferior vena cava diameter
Study NCT03641534 — intervention group
Intervention type: PROCEDURE
Intervention: Passive leg raising test (PLR)
Description: Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
Study NCT03641534 — intervention group
Intervention type: PROCEDURE
Intervention: Orthogonal polarization spectral imaging (OPS)
Description: Measurement of capillary flow in the rectal microcirculation
Study NCT02188277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeomin
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.